Apparently, requiring scientists to state their objectives ahead of time makes a big difference.
Around 2000, the U.S. government ordered researchers conducting clinical trials with federal money to announce ahead of time which medical question they were hoping to answer.
We told you Tuesday about the first-ever White House demo day on Tuesday, which featured 32 early- to growth-stage companies sharing their personal stories and demonstrating their technologies.
And now, some prizes: Six Greater Washington accelerators were awarded prizes from the Small Business Administration, the SBA announced. It was part of a $4.4 million national program encouraging entrepreneurship, according to the SBA.
This paper is a final project from the NIH Foundation for Advanced Education in the Sciences course — TECH 566: Biotechnology Management
Starting up a company is a risky endeavor. From listening to the FAES 566’s course panel discussions this semester, it is clear that there are many challenges a Chief Executive Officer (CEO) will face and try to overcome while starting up and exiting his/her company. Fortunately, we also learned that there are numerous resources available to assist new entrepreneurs in developing strategies for management, funding, technology transactions, and approaches to exit, to name a few.
Blood is one of those things Americans take for granted.
Here, when patients are rushed to the hospital after an accident and are losing a lot of blood, we assume the hospital will have units of donated blood ready to hook up when the ambulance arrives. We don’t think about how much each unit of blood costs — yes, it has a price — because we have health insurance that pays the bill.
After 10 years as a successful veterinarian, Ignacio “Nacho” Pino decided to dedicate himself to work that could bring state-of-the-art biotechnology research to his home of Puerto Rico.
CDI Laboratories—a company he founded in 2008 along with Johns Hopkins University researchers Heng Zhu and Seth Blackshaw, JHU professor emeritus Jef Boeke, and two others (Dan Eichinger and Joe Bonaventura)—aims to produce research-grade protein and antibody products that support scientific research on cancer, autoimmunity, and infectious diseases. The company is one of more than 30 startups being showcased in Washington, D.C., today as part of the first-ever White House Demo Day, which will highlight the work of a diverse group of entrepreneurs from across the country.
Funding and Research Opportunities
The following funding opportunity announcements from the NHLBI or other components of the National Institutes of Health, might be of interest:
Notices:
Program Announcements:
Please note that most links to RFAs, PAs, and Guide Notices will take you to the NIH Web site. RFPs will take you to FedBizOpps. Links to RFPs will not work past their proposal receipt date. Archived versions of RFPs posted on FedBizOpps can be found on the FedBizOpps site using the FedBizOpps search function. Under “Document to Search,” select Archived Documents.
AstraZeneca Plc and Isis Pharmaceuticals Inc. will work together, expanding an earlier collaboration, to seek gene therapy treatments for diseases affecting the heart, kidneys and the body’s metabolism.
AstraZeneca agreed to pay Isis an upfront fee of $65 million plus development and regulatory milestones for each program that the London-based drugmaker advances to clinical development, the companies said in a statement. Isis, based in Carlsbad, California, will earn tiered double-digit royalties on annual sales of each program.
During a tour to Paris, Bruce Springsteen explained that his dream was for the US to adapt a Swedish style welfare state. The famous musician is far from alone in idealizing Nordic policies. The four Nordic nations (Denmark, Finland, Norway and Sweden) are often regarded as prime role-models the policies to be emulated by others. Internationally, advocates of left of centre policies view these countries as examples of how high tax social democratic systems are viable and successful. Paul Krugman, for example, has said: “Every time I read someone talking about the ‘collapsing welfare states of Europe’, I have this urge to take that person on a forced walking tour of Stockholm”.
Baltimore will be the first stop for billionaire investor and entrepreneur Steve Case, who in September kicks off a $1 million investment round.
Case, CEO of the Washington, D.C., venture firm Revolution, plans to invest $1 million in startups in cities that are off the beaten path for most venture capitalists. The Rise of the Rest bus tour kicks off Sept. 28 in Baltimore and will make stops in Philadelphia, Buffalo and Manchester and Portland, Maine.
Today Startup Maryland announced updates to the schedule (September 12 – October 2) and the rough route for the Pitch Across Maryland, the fourth annual state-wide tour and celebration of entrepreneurship and high-growth startup companies.
The Pitch Across Maryland tour will again traverse the state all in the name of celebrating Maryland’s diverse communities of venture building. A sampling of details, key data and results from previous tours follow:
